Skip to content

The Analysis on Dynamic Evaluation of Therapeutic Efficacy and Influencing Factor for 131I in Differentiated Thyroid Cancer: a Retrospective Study

The Analysis on Dynamic Evaluation of Therapeutic Efficacy and Influencing Factor for 131I in Differentiated Thyroid Cancer: a Retrospective Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100041609
Enrollment
Unknown
Registered
2021-01-01
Start date
2020-12-31
Completion date
Unknown
Last updated
2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

differentiated thyroid cancer

Interventions

no lymph node metastasis or lymph node metastasis still present:Nil

Sponsors

The Affiliated Hospital of Qingdao University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Total or subtotal thyroidectomy; (2) Postoperative pathology confirmed that DTC was associated with lymph node metastasis; (3) There was no distant metastasis confirmed by imaging or pathology; (4) Receive at least one 131I treatment; (5) TGAb is negative; (6) The operation and 131I were completed in this hospital with complete case data.

Exclusion criteria

Exclusion criteria: (1) Postoperative pathology confirmed other types of thyroid cancer, such as medullary thyroid cancer, undifferentiated thyroid cancer, lymphoma, etc.; (2) Patients with other malignant tumors, major diseases or autoimmune diseases; (3) Preoperative combination with hyperthyroidism and relevant drug treatment history.

Design outcomes

Primary

MeasureTime frame
Number of lymph node metastases;Thyroglobulin;TSH;

Countries

China

Contacts

Public ContactZhao Wenjuan

The Affiliated Hospital of Qingdao University

18661807103@163.com+86 18661807103

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026